Should You Buy GT Biopharma Inc (GTBP) Stock on Monday?

Monday, December 18, 2023 12:19 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy GT Biopharma Inc (GTBP) Stock on Monday?

Overall market sentiment has been high on GT Biopharma Inc (GTBP) stock lately. GTBP receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

GT Biopharma Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on GTBP!

See Full GTBP Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With GTBP Stock Today?

GT Biopharma Inc (GTBP) stock is lower by -2.68% while the S&P 500 is up 0.57% as of 11:47 AM on Monday, Dec 18. GTBP is down -$0.01 from the previous closing price of $0.25 on volume of 107,393 shares. Over the past year the S&P 500 has gained 24.32% while GTBP is down -80.00%. GTBP lost -$0.29 per share in the over the last 12 months.

More About GT Biopharma Inc

GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. Click Here to get the full Stock Report for GT Biopharma Inc stock.